TDT has large affect on sufferers, households and society – POLITICO

References

¹Galanello R, et al. Orphanet J Uncommon Dis. 2010;5:11.

²Taher, Ali T et al. NEJM. 2021;384(8):727-743.

³N Li et al. Poster BSH23-OR05 introduced at 2023 British Society of Haematology Convention, 23 April 2023.

⁴Jobanputra M, et al. Br J Haematol. 2020;191(5):897-905.

⁵Bush V, et al. Worth in Well being. 2019;22:S851

⁶Sankaran VG, Orkin SH. Chilly Spring Harb Perspect Med.2013;3:a011643.

⁷EU Coverage Suggestions for Thalassaemia and Sickle Cell Illness, TIF, obtainable at: https://thalassaemia.org.cy/positions-policies/position-papers/# Date accessed 25 April 2023.

⁸Musallam KM, et al. Blood. 2012;119(2):364-367.

⁹Shelton E, et al. Journal of Hepatitis 2016;2(1):11.

¹⁰Cappellini MD, et al. Pointers for the Administration of Transfusion Dependent Thalassaemia (TDT). 4th ed. Thalassaemia Worldwide Federation; 2021.

¹¹Lee et al. Blood (2022) 140 (Complement 1): 10869–10870.

¹²Paramore C, et al. Affected person. 2021;14(2):197-208.

¹³Udeze, C. et al. Summary EE58 introduced at 2023 ISPOR Could 2023.

¹⁴Kunzweiler C et al. Summary EE62 introduced at 2023 ISPOR Could 2023.

¹⁵Udeze, C. et al. Summary EE287presented at 2023 ISPOR, Could 2023

¹⁶Udeze, C., et al. Summary 2793 introduced at 2022 European hematology Affiliation Annual Assembly

¹⁷Socié G, Ritz J. Present points in power graft-versus-host illness. Blood. 2014 Jul 17;124(3):374-84.

¹⁸Udeze, C., et al. Blood (2022) 140 (Complement 1): 10741–10742.

¹⁹EMA. Luspatercept SUMMARY OF PRODUCT CHARACTERISTICS. Accessible at: https://www.ema.europa.eu/en/documents/product-information/reblozyl-epar-product-information_en.pdf. Final accessed Could 2023.

²⁰NICE 2022. Luspatercept for treating anaemia brought on by betathalassaemia (terminated appraisal). Accessible at: https://www.nice.org.uk/guidance/ta843/resources/luspatercept-for-treating-anaemia-caused-by-betathalassaemia-terminated-appraisal-pdf-82613490074053. Final accessed: Could 2023.

²¹HAS 2021. REBLOZYL 25 (luspatercept) – ß-thalassemia. Accessible at: https://www.has-sante.fr/jcms/p_3281010/fr/reblozyl-25-ss-thalassemie-luspatercept. Final accessed: Could 2023.

²²FDA. Zynteglo HIGHLIGHTS OF PRESCRIBING INFORMATION. Accessible at: https://www.fda.gov/media/160991/download. Final accessed: Could 2023.

²³EMA. Zynteglo. Accessible at: https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo. Final accessed: Could 2023.

²⁴bluebirdbio. bluebird bio Neighborhood Replace . Accessible at: https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate-COM/Files/bbbcom-community-update-letter.pdf. Final accessed: Could 2023.